Hepatocellular carcinoma (HCC) represents one of the leading causes of cancer mortality
worldwide. While significant advances have been made for the treatment of advanced …

Background & Aims p53 mutations occur frequently in human HCC. Activation of the
mammalian target of rapamycin (mTOR) pathway is also associated with HCC. However, it is …

Dysregulation of pleiotropic growth factors, receptors and their downstream signaling
pathway components represent a central protumorigenic principle in human …

Hepatocellular carcinoma (HCC) is a complex and deadly disease lacking druggable
genetic mutations. The limited efficacy of systemic treatments for advanced HCC implies that …

Hepatocellular carcinoma (HCC) is a common cancer that has the third highest cancer-
related mortality rate worldwide. Although potentially curable by transplantation if detected …

Mechanistic target of rapamycin (mTOR) regulates cell growth, metabolism and aging in
response to nutrients, cellular energy stage and growth factors. mTOR is frequently up …

Simple Summary As the most common primary liver cancer, HCC is a tricky cancer resistant
to systemic therapies. The fibroblast growth factor family and its receptors are gaining more …

In recent years, molecular-targeted agents have been used clinically to treat various
malignant tumors. In May 2009, sorafenib (Nexavar®) was approved in Japan for …

Hepatocellular carcinoma (HCC) is an aggressive malignancy with a poor prognosis.
Effective biomarkers and specific therapeutic targets for HCC are therefore urgently needed …

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most lethal
neoplasm, causing an estimated 700000 deaths annually. Currently HCC has only one …